JACC. Heart failure
-
JACC. Heart failure · Jun 2018
Randomized Controlled TrialRenal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. ⋯ Compared with enalapril, sacubitril/valsartan led to a slower rate of decrease in the eGFR and improved cardiovascular outcomes, even in patients with chronic kidney disease, despite causing a modest increase in UACR.